Urine podocin:nephrin mRNA ratio (PNR) as a podocyte stress biomarker

Nephrology Dialysis Transplantation

Volumn 27, Issue 11, 2012, Pages 4079-4087

  Fukuda, Akihiro ^a   Wickman, Larysa T ^a   Venkatareddy, Madhusudan P ^a   Wang, Su Q ^a   Chowdhury, Mahboob A ^a   Wiggins, Jocelyn E ^a   Shedden, Kerby A ^a   Wiggins, Roger C ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

glomerular disease; podocyte; proteinuria; urine biomarker; urine podocin:nephrin mRNA ratio

Indexed keywords

CREATININE; MESSENGER RNA; NEPHRIN; PODOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRESS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; GLOMERULOSCLEROSIS; GOLD STANDARD; HISTOPATHOLOGY; KIDNEY FAILURE; KIDNEY FIBROSIS; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RAT; RECEIVER OPERATING CHARACTERISTIC; RENAL SYSTEM PARAMETERS; SENSITIVITY AND SPECIFICITY; SYSTOLIC BLOOD PRESSURE; URINE PODOCIN NEPHRIN MRNA RATIO; URINE PROTEIN CREATININE RATIO; URINE VOLUME;

ANIMALS; BIOLOGICAL MARKERS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY DISEASES; KIDNEY GLOMERULUS; MEMBRANE PROTEINS; PODOCYTES; PROTEINURIA; RATS; RATS, INBRED F344; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84869388346     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs313     Document Type: Article

References (44)

1. Kriz W. Podocyte is the major culprit accounting for the progression of chronic renal disease. Microsc Res Tech 2002; 57:189-195. (Pubitemid 34553247)
2. Wiggins R. The spectrum of podocytopathies: a unifying view of glo-merular diseases. Kidney Int 2007; 71:1205-1214. (Pubitemid 46884251)
3. Pagtalunan ME, Miller PL, Jumping-Eagle S et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997; 99:342-348. (Pubitemid 27053474)
4. Meyer TW, Bennett PH, Nelson RG. Podocyte number predicts longterm urinary albumin excretion in Pima Indians with type II diabetes and microalbuminuria. Diabetologia 1999; 42:1341-1344. (Pubitemid 29500971)
5. Steffes MW, Schmidt D, McCrery R et al. International diabetic ne-phropathy study group: glomerular cell number in normal subjects and type I diabetes patients. Kidney Int 2001; 59:2104-2113. (Pubitemid 32467602)
6. White KE, Bilous RW, Marshall SM et al. European study for the prevention of renal disease in type I diabetes (ESPRIT): podocyte number in normotensive type I diabetic patients with albuminuria. Diabetes 2002; 51:3083-3089.
7. Lemley KV, Lafayette RA, Safai M et al. Podocytopenia and disease severity in IgA nephropathy. Kidney Int 2002; 61:1475-1485. (Pubitemid 34304509)
8. Dalla Vestra M, Masiero A, Roiter AM et al. Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes. Diabetes 2003; 52:1031-1035. (Pubitemid 36384274)
9. Wang G, Lai FM, Kwan BC et al. Podocyte loss in human hypertensive nephrosclerosis. Am J Hypertens 2009; 22:300-306.
10. Hara M, Yanagihara T, Itoh M et al. Immunohistochemical and urinary markers of podocyte injury. Pediatr Nephrol 1998; 12:43-48. (Pubitemid 28165780)
11. Hara M, Yanagihara T, Takada T et al. Urinary excretion of podo-cytes reflects disease activity in children with glomerulonephritis. Am J Nephrol 1998; 18:35-41. (Pubitemid 28043794)
12. Nakamura T, Ushiyama C, Suzuki S et al. Urinary excretion of po-docytes in patients with diabetic nephropathy. Nephrol Dial Transplant 2000; 15:1379-1383.
13. Hara M, Yanagihara T, Kihara I. Urinary podocytes in primary focal segmental glomerulosclerosis. Nephron 2001; 89:342-347. (Pubitemid 34701770)
14. Pätäri A, Forsblom C, Havana M et al. Nephrinuria in diabetic ne-phropathy of type 1 diabetes. Diabetes 2003; 52:2969-2974. (Pubitemid 37466867)
15. Vogelmann SU, Nelson WJ, Myers BD et al. Urinary excretion of viable podocytes in health and renal disease. Am J Physiol Renal Physiol 2003; 285: F40-F48. (Pubitemid 36818460)
16. Petermann AT, Pippin J, Krofft R et al. Viable podocytes detach in experimental diabetic nephropathy. Potential mechanism underlying glomerulosclerosis. Nephron Exp Nephrol 2004; 98: e114-e123.
17. Hara M, Yanagihara T, Kihara I et al. Apical cell membranes are shed into urine from injured podocytes: a novel phenomenon of po-docyte injury. J Am Soc Nephrol 2005; 16:408-416. (Pubitemid 41725136)
18. Szeto CC, Lai KB, Chow KM et al. Messenger RNA expression of glomerular podocyte markers in the urinary sediment of acquired proteinuric disease. Clin Chim Acta 2005; 361:182-190.
19. Yu D, Petermann A, Kunter U et al. Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinur-ia. J Am Soc Nephrol 2005; 16:1733-1741. (Pubitemid 41716479)
20. Hara M, Yanagihara T, Kihara I. Cumulative excretion of urinary podocytes reflects disease progression in IgA nephropathy and Schönlein-Henoch purpura nephritis. Clin J Am Soc Nephrol 2007; 2:231-238.
21. Garovic VD, Wagner SJ, Turner ST et al. Urinary podocyte excretion as a marker for preeclampsia. Am J Obstet Gynecol 2007; 196:320.e1-320.e7.
22. Camici M. Urinary detection of podocyte injury. Biomed Pharmac-other 2007; 61:245-249. (Pubitemid 46891727)
23. Wang G, Lai FM, Tam LS et al. Messenger RNA expression of po-docyte-associated molecules in urinary sediment of patients with lupus nephritis. J Rheumatol 2007; 3:2358-2364. (Pubitemid 350230656)
24. Wang G, Lai FM, Lai KB et al. Urinary messenger RNA expression of podocyte-associated molecules in patients with diabetic nephropa-thy treated by angiotensin-converting enzyme inhibitor and angio-tensin receptor blocker. Eur J Endocrinol 2008; 158:317-322. (Pubitemid 351404995)
25. Skoberne A, Konieczny A, Schiffer M. Glomerular epithelial cells in the urine: what has to be done to make them worthwhile? Am J Physiol Renal Physiol 2009; 296: F230-F241.
26. Fukuda A, Wiggins RC. Podocyte biomarkers in urine: relevance and potential. J Clin Metab Diabetes 2011; 2-2:39-44.
27. Sato Y, Wharram BL, Lee SK et al. Urine podocyte mRNAs mark progression of renal disease. J Am Soc Nephrol 2009; 20:1041-1052.
28. Fukuda A, Wichman LT, Venkatareddy MP et al. Angiotensin II-dependent persistent podocyte loss from destabilized glomeruli causes progression of end stage kidney disease. Kidney Int 2012; 81:40-55.
29. Wharram BL, Goyal M, Wiggins JE et al. Podocyte depletion causes glomerulosclerosis: Diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor trans-gene. J Am Soc Nephrol 2005; 16:2941-2952. (Pubitemid 44743492)
30. Kim YH, Goyal M, Kurnit D et al. Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat. Kidney Int 2001; 60:957-968. (Pubitemid 34205795)
31. Sanden SK, Wiggins JE, Goyal M et al. Evaluation of a thick and thin section method for estimation of podocyte number, glomerular volume and glomerular volume per podocyte in rat kidney with Wilms' tumor-1 protein used as a podocyte nuclear marker. J Am Soc Nephrol 2003; 14:2484-2493. (Pubitemid 37169334)
32. Doublier S, Salvidio G, Lupia E et al. Nephrin expression is reduced in human diabetic nephropathy. Evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 2003; 52:1023-1030. (Pubitemid 36384273)
33. Schmid H, Henger A, Cohen C et al. Gene expression profiles of podocyte-associated molecules as diagnostic markers in acquired proteinuric diseases. J Am Soc nephrol 2003; 14:2958-2966. (Pubitemid 37305659)
34. Benigni A, Gagliardini E, Remuzzi G. Changes in glomerular perm-selectivity induced by angiotensin II imply podocyte dysfunction and slit diaphragm protein rearrangement. Semin Nephrol 2004; 24:131-140. (Pubitemid 38387854)
35. Benigni A, Gagliardini E, Tomasoni S et al. Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy. Kidney Int 2004; 65:2193-2200. (Pubitemid 38670005)
36. Bennett MR, Czech KA, Arend LJ et al. Laser capture microdissec-tion- microarray analysis of focal segmental glomerulosclerosis glomeruli. Nephron Exp Nephrol 2007; 107: e30-e40. (Pubitemid 47355799)
37. Garovic VD, Wagner SJ, Petrovic LM et al. Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia. Nephrol Dial Transplant 2007; 22:1136-1143. (Pubitemid 46523429)
38. Ziyadeh FN, Wolf G. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diab Rev 2008; 4:39-45. (Pubitemid 351210971)
39. Wiggins J, Goyal M, Sanden S, Wharram B, Shedden K, Misek D, Kuick R, Wiggins R. Podocyte hypertrophy, 'adaptation' and 'decompensation' associated with glomerular enlargement and glomerulosclerosis in the aging rat: Prevention by calorie restriction. J Am Soc Nephrol 2005; 16:2953-2966. (Pubitemid 44743493)
40. Levey AS, Cattran D, Friedman A. Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the national kidney foundation and the US food and drug administration. Am J Kid Dis 2009; 54:205-226.
41. Stevens LA, Greene T, Levey AS. Surrogate end points for clinical trials of kidney disease progression. Clin J Am Soc Nephrol 2006; 1:874-884.
42. Zandi-Nejad K, Eddy AA, Glassock RJ et al. Why is proteinuria an ominous biomarker of progressive kidney disease? Kidney Int 2004; 66(Suppl 92): S76-89. (Pubitemid 43361438)
43. Kriz W, LeHir M. Pathways to nephron loss starting from glomerular diseases: insights from animal models. Kidney Int 2005; 67:404-419. (Pubitemid 40139832)
44. Nielsen R, Christensen EI. Proteinuria and events beyond the slit. Pediatr Nephrol 2010; 5:813-22.